UK R&D Tax Credit Post-Merger RDEC: 2026/27

UK R&D Tax Credit Post-Merger RDEC 2026/27 Guide

Q: What is the merged R&D tax credit scheme post-April 2024?

April 2024 R&D reform : previous separate SME and RDEC schemes merged into single scheme + new ERIS (Enhanced R&D Intensive Support) for loss-making R&D-intensive SMEs. Statutory basis: Finance Act 2024 + CTA 2009 Part 13 (amended). Pre-merger schemes (accounting periods starting before 1 April 2024): SME scheme = 86% enhancement (130% pre-April 2023 + reduced to 86% from April 2023). RDEC scheme = 20% above-the-line credit (was 13% pre-April 2023). Post-merger (accounting periods starting on/after 1 April 2024) : Standard RDEC-style scheme : 20% expenditure credit applied to qualifying R&D costs. Effective benefit ~15% post-Corporation Tax. ERIS for R&D-intensive SMEs : 27% enhanced credit for loss-making SMEs with 30%+ of total expenditure on qualifying R&D (40% threshold pre-April 2024 reduced). What "merged" means : most companies now use the standard RDEC-style mechanic regardless of size. ERIS preserves enhanced support specifically for small loss-making R&D-intensive companies. Compliance focus : HMRC has dramatically increased R&D claim scrutiny since 2022. Industry estimates 25-40% of claims now reviewed. Schedule 24 FA 2007 penalties applied to over-claims.

Q: What expenditure qualifies for R&D tax credit?

Qualifying R&D expenditure categories (Section 1027-1142 CTA 2009): (1) Staff costs : directly engaged in R&D project. Includes salaries, pensions, NI, bonuses, share scheme costs. Maximum 65% of total qualifying expenditure typical. (2) Externally provided workers : agency staff doing R&D work. 65% of EPW cost qualifies (anti-fraud rule from April 2024). (3) Software + consumables : software licenses, raw materials consumed in R&D process. (4) Cloud computing + data costs : introduced as qualifying expenditure April 2023. AWS, Azure, GCP costs for R&D projects. Data acquisition costs for ML training. (5) Subcontracted R&D : 65% of subcontracted R&D cost qualifies (anti-arbitrage rule from April 2024). (6) Clinical trial volunteer payments : specific to pharma. Non-qualifying : capital expenditure (use Capital Allowances instead), production costs once R&D phase complete, marketing, training (general), legal fees, rent + utilities (apportionment for R&D space possible). Apportionment : where staff or expenditure is split between R&D + non-R&D, must apportion based on time/use. Documented timesheets recommended. Connected party transactions : anti-avoidance rules limit qualifying expenditure on services from connected companies to actual costs (no mark-up). From April 2024 - overseas R&D restrictions : subcontractor/EPW costs only qualify if UK-located (limited exceptions for genuine necessity).

Q: How does ERIS work for loss-making R&D-intensive SMEs?

ERIS (Enhanced R&D Intensive Support) : separate scheme for loss-making SMEs with high R&D intensity. April 2024 reform retained this support after merging standard schemes. Qualifying conditions : (1) SME size : <500 employees AND turnover <€100m OR balance sheet <€86m (consistent with EU SME definition). (2) R&D intensity : qualifying R&D expenditure ≥30% of total trading expenditure (40% threshold pre-April 2024 reduced). (3) Loss-making : company has taxable loss after R&D expenditure deducted. Benefit : 27% enhanced credit on qualifying R&D expenditure. Worked example: £500k qualifying R&D + 35% intensity (qualifies) + £200k taxable loss = £500k × 27% = £135k payable credit. Used to offset losses or surrendered for cash payment. Cash payment : ERIS credits payable to bank account if company has loss + can't use credit against profits. Standard merged scheme comparison : same £500k R&D but in standard merged scheme = £500k × 20% = £100k credit. ERIS provides £35k extra benefit for qualifying intensity. Transition arrangements : pre-April 2024 ERIS used 14% rate; reformed to 27% from April 2024 (Finance Act 2024). Anti-abuse : HMRC scrutinises ERIS claims closely. Intensity calculation must be accurate + supported. Penalties for over-claim up to 100% under Schedule 24 FA 2007.

Q: How do I claim R&D tax credit?

Step-by-step claim process : (1) Pre-notification : from August 2023, NEW R&D claimants must pre-notify HMRC within 6 months of accounting period end (Section 1142D CTA 2009 + 2023 Regulations). Online via HMRC R&D Notification Service. Failure to pre-notify = claim denied. (2) Documentation : (a) Project narrative describing R&D activity, advance sought, uncertainty resolved. ~500-2,000 words per project. (b) Cost calculation with breakdown by category. (c) Director declaration confirming reasonable accuracy. (3) Additional Information Form (AIF) : mandatory from August 2023 (Section 1142A CTA 2009). Includes named officer + claim summary + project details + qualifying expenditure breakdown. Submitted online before / with CT600. (4) File CT600 with R&D claim boxes completed. (5) HMRC review : pre-payment compliance check (likely 30%+ of claims now). Officer reviews AIF + may request supporting evidence. (6) Payment / offset : standard merged scheme reduces CT bill. ERIS payable credit goes to bank account if surrendered. Timeline : simple claims 4-8 weeks. Reviewed claims 3-12 months. Disputed claims potentially 1-3 years via tribunal. Specialist firms : many R&D consultancies prepare claims for fee. Typical 15-25% of credit value as contingent fee. HMRC actively investigating consultancies submitting weak / fraudulent claims. Risk of inflated claims : consultancies sometimes over-claim - directors remain personally liable for accuracy.

Q: What is HMRC compliance focus on R&D claims?

HMRC R&D enforcement dramatically increased 2022-2024 following abuse cases. Statistics : 2023/24 saw ~£1.05bn rejected/reduced R&D claims. ~250 specialist HMRC officers dedicated. Targeting : (1) High-risk sectors : "AI" / "blockchain" / "tech consultancy" firms with thin documentation. (2) High-value claims : claims >£500k automatic review. (3) First-time claimants : pre-notification triggers heightened review for new claimants. (4) Specific consultancies : HMRC publishes naming of disreputable R&D consultancies via Spotlight notices. (5) Pattern matching : R&D intensity inconsistent with sector norms flagged. Compliance check process : HMRC sends initial information request typically within 30-60 days of claim. May request: technical narratives, project plans, time records, supporting invoices, evidence of uncertainty resolution. Response timing : 30 days standard. Extensions possible. Penalty mechanics : Schedule 24 FA 2007. Careless 0-30%. Deliberate 20-70%. Deliberate concealed 30-100%. Plus Schedule 41 FA 2008 failure-to-notify if pre-notification missed. Voluntary withdrawal : if claim weak / unsupportable, withdraw before HMRC formal challenge for better penalty position. Tribunal appeals : First-tier Tax Tribunal cases on R&D 50+ pending 2025-2026. Likely setting new precedents. Industry response : legitimate R&D firms tightening documentation. Many shifting to in-house R&D tax functions vs consultancies.

Q: Can I claim R&D credit retroactively?

Yes - within strict time limits . Standard limit : 2 years from end of accounting period. So claim for year ending 31 March 2025 must be filed by 31 March 2027. Section 1138 CTA 2009. Pre-notification (NEW from August 2023) : even with 2-year claim window, claimants who haven't claimed R&D in prior 3 years must PRE-NOTIFY within 6 months of accounting period end. Section 1142D CTA 2009 + 2023 Regulations. Missed pre-notification = NO RETROACTIVE CLAIM possible. Multiple-year retroactive claims : previously possible to submit 2-3 years of retroactive claims simultaneously. From 2023+ harder due to pre-notification rules - most multi-year retro claims now blocked unless prior claims exist. Worked retroactive scenario : company's accounting period ended 31 March 2025. Did NOT claim R&D in last 3 years. Pre-notification deadline was 30 September 2025. If missed, retro claim for 2024/25 is barred regardless of merit. Existing claimants : companies with R&D claims in prior 3 years don't need pre-notification - standard 2-year window applies. Strategic implications : NEW companies considering R&D claims must pre-notify within 6 months even if claim not yet quantified. Acts as preliminary intent declaration. Specialist advice timing : consult specialist BEFORE year-end if first-time claim contemplated. Pre-notification missed = full claim value lost.

Q: How does R&D credit interact with Patent Box?

Patent Box : separate UK tax relief providing 10% effective CT rate on profits from patented inventions. Statutory basis: CTA 2010 Part 8A. R&D Tax Credit + Patent Box stack : both reliefs can apply to same company's R&D activity → patented product. R&D Tax Credit : applies during R&D phase - costs incurred resolving technical uncertainty. Patent Box : applies post-patent grant - reduces tax on profits from commercialised patent. Worked example : pharmaceutical company spends £10m on R&D over 3 years → £2m R&D credit (20% × £10m, simplified). Patents granted. Sells patented drug for £30m profit/year over 10 years. Patent Box reduces effective CT on patent-attributable profits to 10% (vs 25% main rate) = ~£4.5m/year saving. Combined tax efficiency : R&D credit reduces development cost + Patent Box reduces ongoing commercialisation cost. Significant total benefit for innovative companies. Patent Box qualifying conditions : (a) company must have qualifying IP rights (UK / EPO patents); (b) IP development carried out by company (Nexus approach post-April 2017); (c) IP must derive UK/EPO patent revenues. Patent Box election : opt-in via company tax return. Annual basis. Specialist advice essential : Patent Box involves complex IP attribution calculations + Nexus tracking. R&D + Patent Box specialists often distinct firms.

Q: What is the connection to Capital Allowances for R&D?

R&D Capital Allowances : 100% first-year allowance on capital expenditure incurred wholly + exclusively for R&D activity. Section 437 CAA 2001. Distinction from R&D Tax Credit : R&D Tax Credit : relief on R&D REVENUE expenditure (staff, materials, software, consumables). R&D Capital Allowances : relief on R&D CAPITAL expenditure (lab equipment, R&D-specific machinery, prototyping equipment). Worked example : company spends £200k on lab equipment for new drug development + £500k on staff costs. R&D Capital Allowances claim 100% × £200k = £200k deduction year 1 (saves £40-50k CT). R&D Tax Credit on £500k staff = £100k credit. Combined relief £140-150k. Buildings : capital expenditure on R&D buildings/labs may also qualify for R&D Capital Allowances at 100% first-year allowance. Significant advantage vs standard Structures and Buildings Allowance (3% straight-line). Patent costs : pre-patent costs (filing fees, patent agent fees) potentially qualify for R&D Capital Allowances if part of R&D project. Practical impact : combining R&D Capital Allowances + R&D Tax Credit + Patent Box = maximum UK R&D tax efficiency. Common in life sciences, AI/ML hardware companies, medical devices. Documentation : separate but parallel records. Capital vs revenue expenditure boundary critical - misclassification = HMRC compliance issue.

Comprehensive UK R&D tax credit guide post-April 2024 reform. Merged SME/RDEC standard scheme with 20% above-the-line credit. ERIS (Enhanced R&D Intensive Support) 27% credit for loss-making SMEs with 30%+ R&D intensity. Pre-notification requirement (NEW August 2023) - 6 months from accounting period end. Additional Information Form (AIF) mandatory. 4-test qualifying definition (advance in science/tech, uncertainty, systematic project, UK-located). Qualifying expenditure categories - staff (65% rule), externally provided workers, subcontracted R&D, software + consumables, cloud + data (since April 2023). HMRC compliance focus 2024-2026 (£1bn+ rejected claims). Software R&D tightened guidance. Capital Allowances + Patent Box interaction. Group structure complications. 2024 reform context + 2027+ outlook. Statute - CTA 2009 Part 13, Finance Act 2024. 12-FAQ.

Frequently asked questions

What is the merged R&D tax credit scheme post-April 2024?

April 2024 R&D reform: previous separate SME and RDEC schemes merged into single scheme + new ERIS (Enhanced R&D Intensive Support) for loss-making R&D-intensive SMEs. Statutory basis: Finance Act 2024 + CTA 2009 Part 13 (amended). Pre-merger schemes (accounting periods starting before 1 April 2024): SME scheme = 86% enhancement (130% pre-April 2023 + reduced to 86% from April 2023). RDEC scheme = 20% above-the-line credit (was 13% pre-April 2023). Post-merger (accounting periods starting on/after 1 April 2024): Standard RDEC-style scheme: 20% expenditure credit applied to qualifying R&D costs. Effective benefit ~15% post-Corporation Tax. ERIS for R&D-intensive SMEs: 27% enhanced credit for loss-making SMEs with 30%+ of total expenditure on qualifying R&D (40% threshold pre-April 2024 reduced). What "merged" means: most companies now use the standard RDEC-style mechanic regardless of size. ERIS preserves enhanced support specifically for small loss-making R&D-intensive companies. Compliance focus: HMRC has dramatically increased R&D claim scrutiny since 2022. Industry estimates 25-40% of claims now reviewed. Schedule 24 FA 2007 penalties applied to over-claims.

What qualifies as R&D for UK tax credit purposes?

HMRC definition (BEIS Guidelines on Meaning of R&D for Tax Purposes): project must seek to achieve an advance in science or technology through resolution of scientific or technological uncertainty. Four key tests: (1) Advance in science or technology: project aims to improve existing knowledge, capability, or product/process. Not just commercial novelty - genuine technical advance. (2) Scientific or technological uncertainty: knowledge expert in the field cannot readily deduce. Beyond routine engineering / standard solutions. (3) Systematic project: planned activity with defined start/end + identifiable team + budgets. (4) UK-based qualifying expenditure: from 1 April 2024 ALL R&D activity must be UK-located OR sufficient nexus to UK (specific overseas R&D restrictions). What qualifies as "science or technology": physical sciences, biological sciences, mathematical sciences, engineering, computer science (limited to algorithmic / system architecture advance, NOT just software development), pharmaceuticals, materials science. What DOESN'T qualify: market research, commercial planning, product launching, accountancy / legal innovation, social sciences, arts, humanities, market-driven business model innovation. Common borderline cases: software development (qualifies if genuine technical uncertainty / algorithmic advance; NOT if just writing standard code), AI/ML (qualifies if advancing AI techniques; NOT just using GPT-4 APIs), mobile apps (rarely qualifies - standard mobile dev), website builds (almost never qualifies). HMRC scrutiny 2024+: rejected claims often involved "AI" or "blockchain" terminology without genuine technical advance.

What expenditure qualifies for R&D tax credit?

Qualifying R&D expenditure categories (Section 1027-1142 CTA 2009): (1) Staff costs: directly engaged in R&D project. Includes salaries, pensions, NI, bonuses, share scheme costs. Maximum 65% of total qualifying expenditure typical. (2) Externally provided workers: agency staff doing R&D work. 65% of EPW cost qualifies (anti-fraud rule from April 2024). (3) Software + consumables: software licenses, raw materials consumed in R&D process. (4) Cloud computing + data costs: introduced as qualifying expenditure April 2023. AWS, Azure, GCP costs for R&D projects. Data acquisition costs for ML training. (5) Subcontracted R&D: 65% of subcontracted R&D cost qualifies (anti-arbitrage rule from April 2024). (6) Clinical trial volunteer payments: specific to pharma. Non-qualifying: capital expenditure (use Capital Allowances instead), production costs once R&D phase complete, marketing, training (general), legal fees, rent + utilities (apportionment for R&D space possible). Apportionment: where staff or expenditure is split between R&D + non-R&D, must apportion based on time/use. Documented timesheets recommended. Connected party transactions: anti-avoidance rules limit qualifying expenditure on services from connected companies to actual costs (no mark-up). From April 2024 - overseas R&D restrictions: subcontractor/EPW costs only qualify if UK-located (limited exceptions for genuine necessity).

How does ERIS work for loss-making R&D-intensive SMEs?

ERIS (Enhanced R&D Intensive Support): separate scheme for loss-making SMEs with high R&D intensity. April 2024 reform retained this support after merging standard schemes. Qualifying conditions: (1) SME size: <500 employees AND turnover <€100m OR balance sheet <€86m (consistent with EU SME definition). (2) R&D intensity: qualifying R&D expenditure ≥30% of total trading expenditure (40% threshold pre-April 2024 reduced). (3) Loss-making: company has taxable loss after R&D expenditure deducted. Benefit: 27% enhanced credit on qualifying R&D expenditure. Worked example: £500k qualifying R&D + 35% intensity (qualifies) + £200k taxable loss = £500k × 27% = £135k payable credit. Used to offset losses or surrendered for cash payment. Cash payment: ERIS credits payable to bank account if company has loss + can't use credit against profits. Standard merged scheme comparison: same £500k R&D but in standard merged scheme = £500k × 20% = £100k credit. ERIS provides £35k extra benefit for qualifying intensity. Transition arrangements: pre-April 2024 ERIS used 14% rate; reformed to 27% from April 2024 (Finance Act 2024). Anti-abuse: HMRC scrutinises ERIS claims closely. Intensity calculation must be accurate + supported. Penalties for over-claim up to 100% under Schedule 24 FA 2007.

How do I claim R&D tax credit?

Step-by-step claim process: (1) Pre-notification: from August 2023, NEW R&D claimants must pre-notify HMRC within 6 months of accounting period end (Section 1142D CTA 2009 + 2023 Regulations). Online via HMRC R&D Notification Service. Failure to pre-notify = claim denied. (2) Documentation: (a) Project narrative describing R&D activity, advance sought, uncertainty resolved. ~500-2,000 words per project. (b) Cost calculation with breakdown by category. (c) Director declaration confirming reasonable accuracy. (3) Additional Information Form (AIF): mandatory from August 2023 (Section 1142A CTA 2009). Includes named officer + claim summary + project details + qualifying expenditure breakdown. Submitted online before / with CT600. (4) File CT600 with R&D claim boxes completed. (5) HMRC review: pre-payment compliance check (likely 30%+ of claims now). Officer reviews AIF + may request supporting evidence. (6) Payment / offset: standard merged scheme reduces CT bill. ERIS payable credit goes to bank account if surrendered. Timeline: simple claims 4-8 weeks. Reviewed claims 3-12 months. Disputed claims potentially 1-3 years via tribunal. Specialist firms: many R&D consultancies prepare claims for fee. Typical 15-25% of credit value as contingent fee. HMRC actively investigating consultancies submitting weak / fraudulent claims. Risk of inflated claims: consultancies sometimes over-claim - directors remain personally liable for accuracy.

What is HMRC compliance focus on R&D claims?

HMRC R&D enforcement dramatically increased 2022-2024 following abuse cases. Statistics: 2023/24 saw ~£1.05bn rejected/reduced R&D claims. ~250 specialist HMRC officers dedicated. Targeting: (1) High-risk sectors: "AI" / "blockchain" / "tech consultancy" firms with thin documentation. (2) High-value claims: claims >£500k automatic review. (3) First-time claimants: pre-notification triggers heightened review for new claimants. (4) Specific consultancies: HMRC publishes naming of disreputable R&D consultancies via Spotlight notices. (5) Pattern matching: R&D intensity inconsistent with sector norms flagged. Compliance check process: HMRC sends initial information request typically within 30-60 days of claim. May request: technical narratives, project plans, time records, supporting invoices, evidence of uncertainty resolution. Response timing: 30 days standard. Extensions possible. Penalty mechanics: Schedule 24 FA 2007. Careless 0-30%. Deliberate 20-70%. Deliberate concealed 30-100%. Plus Schedule 41 FA 2008 failure-to-notify if pre-notification missed. Voluntary withdrawal: if claim weak / unsupportable, withdraw before HMRC formal challenge for better penalty position. Tribunal appeals: First-tier Tax Tribunal cases on R&D 50+ pending 2025-2026. Likely setting new precedents. Industry response: legitimate R&D firms tightening documentation. Many shifting to in-house R&D tax functions vs consultancies.

Software development R&D - what qualifies + what doesn't?

HMRC software R&D guidance significantly tightened 2023-2024. Many "software development" claims previously accepted now rejected. What qualifies (software-specific R&D): (1) Algorithmic advance: developing new algorithms not in existing literature. Examples: novel ML model architectures, new cryptographic protocols, novel optimisation techniques. (2) System architecture innovation: solving genuine architectural uncertainty - high-scale distributed systems with no proven blueprint, real-time low-latency at unprecedented throughput, novel database architectures. (3) Hardware-software integration: drivers / firmware for new hardware. Embedded systems with genuine technical novelty. (4) Specific industry technical innovations: medical imaging algorithms, genomics processing, materials simulation, etc. What does NOT qualify (most software work): standard mobile app development, e-commerce sites, marketing tools, generic SaaS platforms, CRM customisation, standard React/Vue/Angular development, API integration work, database query optimisation using known indexes, standard cloud migration, applying GPT-4/Claude APIs to business problems. Common HMRC rejection reasons: "AI" terminology used but project is just calling OpenAI API; "blockchain" terminology but no novel consensus mechanism / cryptography; "scalability" claimed but using standard AWS auto-scaling. Documentation requirement: project narrative must explain WHAT specific technical uncertainty existed, WHAT was tried + failed, HOW resolution advanced the field beyond available solutions. Industry impact: many software consultancies + agencies who claimed R&D pre-2023 have ceased claims. Legitimate algorithmic / systems R&D continues to qualify.

Can I claim R&D credit retroactively?

Yes - within strict time limits. Standard limit: 2 years from end of accounting period. So claim for year ending 31 March 2025 must be filed by 31 March 2027. Section 1138 CTA 2009. Pre-notification (NEW from August 2023): even with 2-year claim window, claimants who haven't claimed R&D in prior 3 years must PRE-NOTIFY within 6 months of accounting period end. Section 1142D CTA 2009 + 2023 Regulations. Missed pre-notification = NO RETROACTIVE CLAIM possible. Multiple-year retroactive claims: previously possible to submit 2-3 years of retroactive claims simultaneously. From 2023+ harder due to pre-notification rules - most multi-year retro claims now blocked unless prior claims exist. Worked retroactive scenario: company's accounting period ended 31 March 2025. Did NOT claim R&D in last 3 years. Pre-notification deadline was 30 September 2025. If missed, retro claim for 2024/25 is barred regardless of merit. Existing claimants: companies with R&D claims in prior 3 years don't need pre-notification - standard 2-year window applies. Strategic implications: NEW companies considering R&D claims must pre-notify within 6 months even if claim not yet quantified. Acts as preliminary intent declaration. Specialist advice timing: consult specialist BEFORE year-end if first-time claim contemplated. Pre-notification missed = full claim value lost.

How does R&D credit interact with Patent Box?

Patent Box: separate UK tax relief providing 10% effective CT rate on profits from patented inventions. Statutory basis: CTA 2010 Part 8A. R&D Tax Credit + Patent Box stack: both reliefs can apply to same company's R&D activity → patented product. R&D Tax Credit: applies during R&D phase - costs incurred resolving technical uncertainty. Patent Box: applies post-patent grant - reduces tax on profits from commercialised patent. Worked example: pharmaceutical company spends £10m on R&D over 3 years → £2m R&D credit (20% × £10m, simplified). Patents granted. Sells patented drug for £30m profit/year over 10 years. Patent Box reduces effective CT on patent-attributable profits to 10% (vs 25% main rate) = ~£4.5m/year saving. Combined tax efficiency: R&D credit reduces development cost + Patent Box reduces ongoing commercialisation cost. Significant total benefit for innovative companies. Patent Box qualifying conditions: (a) company must have qualifying IP rights (UK / EPO patents); (b) IP development carried out by company (Nexus approach post-April 2017); (c) IP must derive UK/EPO patent revenues. Patent Box election: opt-in via company tax return. Annual basis. Specialist advice essential: Patent Box involves complex IP attribution calculations + Nexus tracking. R&D + Patent Box specialists often distinct firms.

What is the connection to Capital Allowances for R&D?

R&D Capital Allowances: 100% first-year allowance on capital expenditure incurred wholly + exclusively for R&D activity. Section 437 CAA 2001. Distinction from R&D Tax Credit: R&D Tax Credit: relief on R&D REVENUE expenditure (staff, materials, software, consumables). R&D Capital Allowances: relief on R&D CAPITAL expenditure (lab equipment, R&D-specific machinery, prototyping equipment). Worked example: company spends £200k on lab equipment for new drug development + £500k on staff costs. R&D Capital Allowances claim 100% × £200k = £200k deduction year 1 (saves £40-50k CT). R&D Tax Credit on £500k staff = £100k credit. Combined relief £140-150k. Buildings: capital expenditure on R&D buildings/labs may also qualify for R&D Capital Allowances at 100% first-year allowance. Significant advantage vs standard Structures and Buildings Allowance (3% straight-line). Patent costs: pre-patent costs (filing fees, patent agent fees) potentially qualify for R&D Capital Allowances if part of R&D project. Practical impact: combining R&D Capital Allowances + R&D Tax Credit + Patent Box = maximum UK R&D tax efficiency. Common in life sciences, AI/ML hardware companies, medical devices. Documentation: separate but parallel records. Capital vs revenue expenditure boundary critical - misclassification = HMRC compliance issue.

How are R&D claims affected by group structures?

Group company complications: R&D tax credit rules treat connected/group companies as single entity for some purposes. SME size test: aggregates with associated companies (Section 156-160 CTA 2010 connected companies rule). Holding company + subsidiaries combined. R&D intensity (ERIS): tested at group level if connected. Single small subsidiary's R&D intensity diluted by non-R&D group activities. Subcontracted R&D between group companies: anti-avoidance rules. Cost claimed is the actual subcontractor's cost, not invoiced amount (to prevent mark-up arbitrage). Section 1133 CTA 2009. Externally provided workers from group: similar anti-avoidance + 65% restriction from April 2024. Loss surrender within group: R&D-generated losses can be surrendered to other group companies for relief. Section 99 CTA 2010. Worked group example: UK holding company + R&D-focused subsidiary + commercial sales subsidiary. R&D subsidiary spends £2m on qualifying R&D + has £1.5m loss. Group's total trading expenditure £8m. R&D intensity 25% - below 30% ERIS threshold. Standard merged scheme applies: £2m × 20% = £400k credit. Compare if no group: R&D-only company at £2m R&D + £500k other = 80% R&D intensity = ERIS qualifying: £2m × 27% = £540k. Group restructuring: separating R&D operations into standalone subsidiary can unlock ERIS. Specialist advice essential.

What is the future of UK R&D tax relief 2027 onwards?

2024 Conservative pre-election position: R&D credit reforms confirmed + planned compliance focus continued. 2024 Labour post-election position: broadly supportive but considering further reform. Likely changes 2026-2028: (1) Further compliance tightening: pre-notification rules may extend to all claimants (not just new). (2) ERIS threshold review: 30% R&D intensity may shift up/down based on uptake data. (3) Sector-specific schemes: green/sustainability R&D enhanced credit possible. AI-focused enhanced credit consultation. (4) Patent Box reform: ongoing post-BEPS Action 5 nexus refinement. (5) Capital Allowances integration: potential unification of R&D revenue + capital relief into single scheme. (6) Cross-border R&D: April 2024 UK-only requirement may face WTO/trade dispute challenges. Possible adjustment 2027+. (7) Digital + AI R&D guidance: HMRC updating BEIS guidelines to better address software/AI R&D in 2025-2026. (8) Penalty regime alignment: R&D-specific penalties may emerge separate from Schedule 24 FA 2007. For UK R&D firms: maintain meticulous documentation. Invest in specialist tax functions. Use established R&D advisory firms with track records. Avoid contingent-fee consultancies offering "guaranteed" claims - these are HMRC enforcement targets. Long-term: UK government committed to R&D investment as economic policy priority. £20bn+ public R&D investment commitments confirm direction. R&D tax relief will remain - but compliance bar will rise.